Accueil
Détail de l'auteur
Documents disponibles écrits par cet auteur
Ajouter le résultat dans votre panier Faire une suggestion Affiner la rechercheArticle : Périodique
N. MESSINA ; P. MARINELLI-CASEY ; M. HILLHOUSE ; R. RAWSON ; J. HUNTER ; A. ANG |ENGLISH : Women report extensive histories of childhood abuse, often leading to addiction. Studies assessing the same effects for men are lacking. This study describes childhood adverse events (CAEs) among methamphetamine (MA)-dependent men an[...]Article : Périodique
L. J. MOONEY ; S. NIELSEN ; A. SAXON ; M. HILLHOUSE ; C. THOMAS ; A. HASSON ; D. STABLEIN ; J. McCORMACK ; R. LINDBLAD ; W. LING |BACKGROUND: Effective medications to treat cocaine dependence have not been identified. Recent pharmacotherapy trials demonstrate the potential efficacy of buprenorphine (BUP) (alone or with naltrexone) for reducing cocaine use. The National Ins[...]Article : Périodique
S. E. BACK ; R. L. PAYNE ; A. H. WAHLQUIST ; R. E. CARTER ; Z. STROUD ; L. HAYNES ; M. HILLHOUSE ; K. T. BRADY ; W. LING |Background: Accumulating evidence indicates important gender differences in substance use disorders. Little is known, however, about gender differences and opioid use disorders. Objectives: To compare demographic characteristics, substance use s[...]Article : Périodique
W. LING ; P. JACOBS ; M. HILLHOUSE ; A. HASSON ; C. THOMAS ; T. FREESE ; S. SPARENBORG ; D. McCARTY ; R. WEISS ; A. SAXON ; A. COHEN ; M. STRAUS ; G. BRIGHAM ; D. LIU ; P. McLAUGHLIN ; B. TAI |The National Institute on Drug Abuse (NIDA) established the National Drug Abuse Treatment Clinical Trials Network (CTN) in 1999 to bring researchers and treatment providers together to develop a clinically relevant research agenda. Initial CTN e[...]Périodique
R. GONZALES ; P. MARINELLI-CASEY ; M. HILLHOUSE ; J. HUNTER ; R. A. RAWSON ; L. MOONEY ; A. ANG | 2008ENGLISH : Epidemiological trends of hepatitis infections among methamphetamine (MA)-dependent individuals are important public health and policy issues. The burden of such infections among MA-dependent users has not been widely studied. This l[...]Périodique
W. LING ; L. AMASS ; S. SHOPTAW ; J. J. ANNON ; M. HILLHOUSE ; D. BABCOCK ; BRIGHMA G. ; J. HARRER ; M. REID ; MUIR J. ; BUCHAN B. ; ORR D. ; G. WOODY ; J. KREJCI ; D. ZIEDONIS ; Buprenorphine Study Protocol Group | 2005FRANÇAIS : L'étude a porté sur 113 patients hospitalisés (77 sous buprénorphine-naloxone, 36 sous clonidine) et 231 patients en traitement ambulatoire (157 sous buprénorphine-naloxone, 74 sous clonidine). Les critères d'évaluation du traitemen[...]Article : Périodique
M. HILLHOUSE ; C. P. CANAMAR ; G. DORAIMANI ; C. THOMAS ; A. HASSON ; W. LING |Background: Clinical parameters for determining buprenorphine dose have not been adequately examined in treatment outcome research. Objectives: This study is a secondary analysis of data collected in a recently completed comparison of buprenorph[...]Article : Périodique
Y. I. HSER ; A. J. SAXON ; D. HUANG ; A. HASSON ; C. THOMAS ; M. HILLHOUSE ; P. JACOBS ; C. TERUYA ; P. McLAUGHLIN ; K. WIEST ; A. COHEN ; W. LING |Aims: To examine patient and medication characteristics associated with retention and continued illicit opioid use in methadone (MET) versus buprenorphine/naloxone (BUP) treatment for opioid dependence. Design, settings and participants: This s[...]
